Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Saraceno

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The British Journal of Dermatology|October 13, 2006
The role of neuropeptides in psoriasisR Saraceno, C E Kleyn, G Terenghi, et al.
Expert Opinion on Drug Safety|January 31, 2017
Safety evaluation of apremilast for the treatment of psoriasisA Dattola, E Del Duca, R Saraceno, et al.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia|May 14, 2014
Topical lactoferrin can improve stable psoriatic plaqueR Saraceno, T Gramiccia, S Chimenti, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 22, 2016
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective studyA Chiricozzi, A Zangrilli, M Bavetta, et al.
Journal of Biological Regulators and Homeostatic Agents|October 25, 2013
High density cholesterol level as predictor of clinical response to anti-TNF-alpha therapy in psoriatic patientsR Saraceno, S Rizza, S Faleri, et al.
European Review for Medical and Pharmacological Sciences|November 26, 2008
Does metabolic syndrome influence psoriasis?R Saraceno, M Ruzzetti, M U De Martino, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 6, 2014
PSOCUBE, a multidimensional assessment of psoriasis patients as a both clinically/practically sustainable and evidence-based algorithmD Linder, G Altomare, S Amato, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 21, 2015
Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapyA Chiricozzi, M V Cannizzaro, G A Salandri, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The British Journal of Dermatology|October 13, 2006
The role of neuropeptides in psoriasisR Saraceno, C E Kleyn, G Terenghi, et al.
Expert Opinion on Drug Safety|January 31, 2017
Safety evaluation of apremilast for the treatment of psoriasisA Dattola, E Del Duca, R Saraceno, et al.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia|May 14, 2014
Topical lactoferrin can improve stable psoriatic plaqueR Saraceno, T Gramiccia, S Chimenti, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 22, 2016
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective studyA Chiricozzi, A Zangrilli, M Bavetta, et al.
Journal of Biological Regulators and Homeostatic Agents|October 25, 2013
High density cholesterol level as predictor of clinical response to anti-TNF-alpha therapy in psoriatic patientsR Saraceno, S Rizza, S Faleri, et al.
European Review for Medical and Pharmacological Sciences|November 26, 2008
Does metabolic syndrome influence psoriasis?R Saraceno, M Ruzzetti, M U De Martino, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 6, 2014
PSOCUBE, a multidimensional assessment of psoriasis patients as a both clinically/practically sustainable and evidence-based algorithmD Linder, G Altomare, S Amato, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 21, 2015
Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapyA Chiricozzi, M V Cannizzaro, G A Salandri, et al.
Pageof 2